Repare Therapeutics Inc. reported its financial results for the third quarter ended September 30, 2024, with collaboration agreement revenue at $0, a decrease from $2.159 million in Q3 2023. The company posted a net loss of $(34.406) million for the quarter, compared to a net loss of $(18.879) million in the prior year period.
Research and development expenses decreased to $28.401 million in Q3 2024 from $32.709 million in Q3 2023, reflecting ongoing cost management. General and administrative expenses also saw a reduction, falling to $6.444 million from $7.868 million year-over-year.
Operationally, Repare dosed the first patient in its Phase 1 POLAR trial for RP-3467 and presented Phase 1 data for camonsertib in combination with radiotherapy at the ASTRO annual meeting. The company remains on track to report data from the MYTHIC dose expansion clinical trial in December 2024, with plans to begin a registrational trial in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.